Shares of Bio-Path Holdings Inc (NASDAQ:BPTH) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus target price of $28.00 for the company and are anticipating that the company will post ($0.74) earnings per share for the current quarter, according to Zacks. Zacks has also given Bio-Path an industry rank of 48 out of 255 based on the ratings given to related companies.
A number of research firms have recently commented on BPTH. ValuEngine upgraded Bio-Path from a “hold” rating to a “buy” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Bio-Path in a report on Friday, August 16th.
Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.27). Equities analysts predict that Bio-Path will post -3.2 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in BPTH. Morgan Stanley raised its position in shares of Bio-Path by 19,858.0% during the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after buying an additional 19,858 shares during the period. Gainplan LLC purchased a new stake in shares of Bio-Path during the 1st quarter valued at approximately $204,000. BlackRock Inc. raised its position in shares of Bio-Path by 17.5% during the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after buying an additional 6,978 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Bio-Path by 10.3% during the 2nd quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock valued at $374,000 after buying an additional 2,601 shares during the period. 9.48% of the stock is currently owned by hedge funds and other institutional investors.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Article: Straddles
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.